Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.
iCo-007 may also have a potential for treatment of certain oncology indications, including ovarian cancer. 007 is nearing completion of Phase 1. Because of the nature of ongoing tests iCo has had hints of what might be seen in Phase Two trials, Confidence, as a result of early trials, is very high. The next step is to either partner develop the compound or raise sufficient capital to enter into Phase II trials. iCo-008 - Severe Ocular Allergies ~$100M+. - 008 is ready for Phase 2 in vernal keratoconjunctivitis (“VKC”). The next step is to partner compound for VKC or potentially another disease (such as asthma, which has a similar underlying disease biology). If iCo partners for a different disease than VKC, some additional pre-clinical work would be required. iCo-009 - Fungal & Parasitic Infections ~$1B+. Also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration. AmpB works, its been around since the fifties and is the standard against which all other drugs in this class are measured. The problem with the drug is how it was delivered. It now seems a self-administered (no hospital stay, no toxicity issues), oral formulation of AmpB is attainable. 009 is late pre-clinical stage. The next steps are to complete preclinical toxicology studies and then launch a Phase 1 safety trial.
Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.
iCo-007 may also have a potential for treatment of certain oncology indications, including ovarian cancer. 007 is nearing completion of Phase 1. Because of the nature of ongoing tests iCo has had hints of what might be seen in Phase Two trials, Confidence, as a result of early trials, is very high. The next step is to either partner develop the compound or raise sufficient capital to enter into Phase II trials. iCo-008 - Severe Ocular Allergies ~$100M+. - 008 is ready for Phase 2 in vernal keratoconjunctivitis (“VKC”). The next step is to partner compound for VKC or potentially another disease (such as asthma, which has a similar underlying disease biology). If iCo partners for a different disease than VKC, some additional pre-clinical work would be required. iCo-009 - Fungal & Parasitic Infections ~$1B+. Also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration. AmpB works, its been around since the fifties and is the standard against which all other drugs in this class are measured. The problem with the drug is how it was delivered. It now seems a self-administered (no hospital stay, no toxicity issues), oral formulation of AmpB is attainable. 009 is late pre-clinical stage. The next steps are to complete preclinical toxicology studies and then launch a Phase 1 safety trial.